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Background: In this retrospective study, we evaluated the prognostic effect of positive lymph-node ratio (pLNR) on
patients with stage III colorectal cancer (CRC). Our paper is the first analysis, to our knowledge, to deal with such
data from the Middle East.
Methods: We analyzed the clinicopathological data of 535 patients diagnosed with colorectal cancer at our
institution between 1983 and 2003. The 164 patients diagnosed with stage III disease were divided into two
categories based on lymph-node ratio (LNR) being the ratio of positive lymph nodes over total lymph nodes
dissected: LNR ≤0.4 and LNR >0.4. We used Kaplan-Meier and Cox proportional hazard models to evaluate the
prognostic effect of pLNR.
Results: The 10-year survival rate for the patients with stage IIIA, IIIB and IIIC cancers were 76%, 56% and 0%
respectively (P= 0.014). Using pLNR of 0.4 as the cutoff point was found to yield clinically and significant results,
with a significant difference in the outcomes of patients with pLNR ≤0.4 compared to those with pLNR >0.4
(hazard ratio = 5.25, 95% confidence interval = 1.2 to 22.1, P= 0.02).
Conclusion: The ratio-based staging (pLNR) of CRC is a more accurate and clinically useful prognostic method than
the number of positive LNs resected or the total number of LNs retrieved for predicting the course of patients with
stage III CRC.
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Colorectal cancer (CRC) is the third most common can-
cer in both female and male populations [1]. Currently,
its progression is staged using the TNM (tumor, node,
metastasis) staging system according to tumor size,
lymph-node involvement and distant metastases, as
recommended by the American Joint Committee on
Cancer (AJCC) [2]. However, many investigators have
questioned the prognostic power of the TNM system be-
cause of the possibility of stage migration, and have pro-
posed alternative prognostic methods.* Correspondence: as04@aub.edu.lb
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reproduction in any medium, provided the orOne notable alternative bases a patient’s prognosis
upon the total number of LNs resected. This concept has
long been debated in the literature. Many studies have
shown that a higher number of LNs retrieved leads to
more accurate staging and apparently improved survival
outcomes [3-8]. Furthermore, a study conducted by the
National Cancer Institute (NCI) involving 60,000
patients illustrated a relationship between the number of
resected positive LNs and the survival rate in stage III
patients [9]. This relationship has driven studies that
have attemped to set recommendations for the number
of LNs that should be resected. The NCI and the Royal
College of Pathologists (RCP) agree on the recommenda-
tion for a minimum of 12 LNs to be resected [10].
Some researchers have also investigated the import-
ance of the number of negative LNs retrieved on the. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.









Total LNs resected 23.6
Mean 20.86
Range 2 to 88
SD 15.2
< 12 38
≥ 12 123 76.4
Grade
Well-differentiated 6 4
Moderately differentiated 93 61.6
Poorly differentiated 52 34.4
N staging
N1 (1 to 3 LNs) 96 60.4
N2 (4+ LNs) 63 39.6
LN, LNs.
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this area.
Methods such as using the positive LN ratio (pLNR;
the number of positive LNs divided by the total number
of LNs resected) have been reported as significant prog-
nostic factors in malignancies of the pancreas, stomach,
bladder, breast and esophagus [12-15], but the import-
ance of the pLNR as a prognostic factor in colon cancer
is still being explored.
In this retrospective study, we aimed to evaluate the
importance of pLNR as a prognostic parameter on the
survival of patients diagnosed with stage III colon cancer
in our population, and to compare its prognostic power
against other methods, such as the total number of LNs
and the number of positive LNs resected. To our know-
ledge, it is the first study to deal with this topic in the
Middle East, hence we relied on the world literature for
purposes of comparison and references.
Methods
The study enrolled 535 patients who were diagnosed
with CRC at our institution between 1983 and 2003. Of
the 535 patients, 164 were diagnosed with stage III dis-
ease, which constituted the sample to be analyzed. The
clinicopathological variables reviewed included age at
presentation, gender, personal and family medical his-
tory, social habits, symptoms, sites of neoplasms, diag-
nostic tools, pathology results, grade, TNM staging, type
of surgery undergone, adjuvant therapy, and survival
rate.
We defined survival rate as overall survival from the
time of diagnosis to either the time of death or the last
follow-up. Tumor grade was classified as low-grade (well
or moderately differentiated) and high-grade (poorly dif-
ferentiated, anaplastic, or undifferentiated). Curative re-
section was defined as clear pathological margins after
surgery, and the follow-up period was 10 years.
Statistical analysis
Abstracted data from the medical records of the 535
patients were coded and analyzed using SPSS(software,
version 18; SPSS Inc., Chicago, IL, USA). Summary sta-
tistics were computed for patients with stage III disease.
Survival rates at 1, 5 and 10 years were computed using
the Kaplan-Meier method, and the log rank test was
used to calculate the P-values for the different variables.
A multivariate model using the Cox proportionate haz-
ard technique was created using age and gender of the
participants as control variables, and all significant vari-
ables at the bivariate level, as well as important prognos-
tic variables such as treatment and number of positive
LNs. Coefficients and standard errors were exponen-
tiated to create hazard ratios (HR) and 95% confidence
intervals. P< 0.05 was considered significant.Results
Clinicopathologic characteristics of the patients
Of the 164 patients diagnosed with stage III disease, 79
(48.2%) were male and 85 (51.8%) were female. The
mean age at presentation was 57.05 years (range 12–97)
(Table 1).
Presenting symptoms varied, and included: change in
bowel habits (92 patients; 56.1%), abdominal pain (85;
51.8%), bleeding per rectum (80; 48.8%), weight loss (78;
47.6%), anemia (20;12.2%) and abdominal mass (2; 1.2%).
There were 56 patients (34.1%) diagnosed with left
colon tumors and 27 patients (16.4%) with right-sided
cancers. Rectal cancer was present in 35 patients (21.3%)
while the transverse colon was involved in 5 patients
(3%). Data were missing for 41 patients (25%).
Colonoscopy was performed in 72 patients (45%), bar-
ium enema in 39 (24.4%), sigmoidoscopy in 17 (10.6%),
and CT scan in 16 (10%). Other investigations included
kidney, ureter, and bladder X-ray, and digital rectal
examination, and diagnosis was an incidental findings for
some patients.Grade and stage
The 164 stage III patients were further subdivided into
IIIA (14; 8.5%), IIIB (108; 65.8%), and IIIC (42; 25.6%).
Adenocarciomas were moderately differentiated in 93
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(34.4%) and well differentiated in 6 patients (4%).Treatment
Of the 164 patients, 159 (97%) underwent surgery as part
of their treatment, with 26.8% undergoing low anterior
resection and 25% undergoing right hemicolectomy.
Only three patients did not undergo any surgery, and
data were missing for 2 patients (1.2%).
Neoadjuvant chemotherapy was given to 8 patients
(4.9%), adjuvant chemotherapy to 81 patients (49.4%)
and radiotherapy to 44 patients (26.8%).LN and LNR
The number of resected LNs (mean ± standard deviation)
was 20.86 ± 15.22 (range 2–88).
Based on the total number of LNs, patients were
divided into two groups, those with fewer than 12 LNs
resected (LN1 <12) and those with 12 or more nodes
resected (LN2 ≥12); 38 patients (23.6%) had LN1 <12
and 123 (76.4%) had ≥12 (Table 1; Figure 1a).
We then divided our population according to the num-
ber of positive LNs retrieved, based on the AJCC classifi-
cation; 96 patients (60.4%) were classified as N1 and 63
(39.6%) as N2.
We further divided the patients into two groups based
on the LNR: 0 to ≤ 0.4 (116 patients; 74.8%) and> 0.4
(41; 25.2%) (Figure 1b).
Moreover, when stratifying our data according to
positive LN and LNR we got the results as cited in
Table 2.Figure 1 Distribution of the number of dissected LNs (LNs). (a) On ave
dissected LNs showed that most of the cases had between 2 and 40 LNs re
scattered cases with a higher number of dissected LNs. (b) Distribution of t
average ratio of positive to dissected LNs was 0.29 (median 0.17), with 50%
between 0.01 and 0.42. There is a a positive skew to the right.Univariate analysis
Stratifying stage III patients alone, survival at 1, 5 and
10 years, respectively, was 91%, 75.8% and 75.8% for
stage IIIA; 94%, 77.1% and 56% for stage IIIB, and 84.7%,
22% and 0% for stage IIIC respectively (Table 3,
Figure 2).
Survival for patients graded N1 and N2 was 58.4% and
19.2% at 10 years respectively (Table 3, Figure 3).
The total number of LNs resected was not found to be
a significant predictor of survival under univariate ana-
lysis (P= 0.45), but there was a significant proportional
correlation between the total number of LNs resected
and the number of positive LNs retrieved (P< 0.01)
(Table 4).
Survival at 1, 5 and 10 years was 94.1%, 77.3% and
60.6%, respectively, for patients with LNR of 0< to ≤ 0.4,
and 86.2%, 40.6% and 0%, respectively, for patients with
LNR >4, survival at 1, 5 and 10 years was (Table 3,
Figure 4).
Multivariate analysis
The Cox proportionate hazard model was used to
analyze survival rates, and controlled for age, gender,
stage III strata (A B, and C), adjuvant therapy, number
of positive LNs, and pLNR. LNR> 0.4, controlled for all
the other variables, gave HR= 5.25, 95% CI = 1.2 to 22.1.
P= 0.02 (Table 5).
Discussion
Accurate staging of colorectal cancer is essential for ap-
propriate therapeutic planning. The TNM staging system
has taken over from the pathological Duke’s staging sys-
tem, however it provides limited prognostic informationrage, 21 lymph nodes were dissected (median 18). The distribution of
moved, with the distribution skewed positively to the right by some
he ratio of positive to dissected LNs (lymph-node ratio; LNR). The
of the cases being between 0.01 and 0.17, and 75% of the cases
Table 2 Cross tabulation of the variables according to LNR and positive LN
Characteristics LNR N (%) P-value Positive LN P-value
0 – 0.4 > 0.4 1 – 3 4+
Age 38 (69.1) 17 (30.9) 0.743 31 (55.4) 25 (44.6) 0.32
<50 25 (78.1) 7 (21.9) 17 (53.1) 15 (46.9)
50 to 60 28 (77.8) 8 (22.2) 26 (72.2) 10 (27.8)
61 to 70 26 (74.3) 9 (25.7) 22 (62.9) 13 (37.1)
> 71
Stage III
IIIA 12 (100) 0 (0) < 0.001 13 (100) 0 (0) < 0.01
IIIB 95 (88) 13 (12) 81 (75) 27 (25)
IIIC 10 (26.3) 28 (73.7) 2 (5.3) 36 (94.7)
Adjuvant chemotherapy
No 58 (71.6) 23 (28.4) 0.356 50 (61.7) 31 (38.3) 0.73
Yes 31 (79.5) 8 (20.5) 26 (65) 14 (35)
Gender
Female 65 (80.2) 16 (19.8) 0.068 44 (57.1) 33 (42.9) 0.42
Male 52 (67.5) 25 (32.5) 52 (63.4) 30 (36.6)
LNs resected
0 – 11 25 (71.4) 10 (28.6) 0.688 27 (77.1) 8 (22.9) 0.02
≥ 12 92 (74.8) 31 (25.2) 68 (55.3) 55 (44.7)
Grade
Well-differentiated 6 (100) 0 (0) 0.002 5 (83.3) 1 (16.7) 0.21
Moderately differentiated 75 (82.4) 16 (17.6) 58 (63) 34 (37)
Poorly differentiated 29 (58) 21 (42) 26 (52) 24 (48)
Recurrence
No 23 (76.7) 7 (23.3) 0.923 16 (53.3) 14 (46.7) 0.11
Yes 50 (75.8) 16 (24.2) 47 (70.1) 20 (29.9)
LNs, Lymph Nodes.
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III disease. Novel prognostic methods based on three dif-
ferent parameters had been investigated: the total num-
ber of LNs collected the number of positive LNs
retrieved, and the positive LNR.
The aim of our retrospective study was to compare
and re-evaluate different approaches for CRC prognosis
in our population of patients with stage III disease.
According to the AJCC [2], stage III CRC is defined
by the depth of tumor invasion and the extent of LN in-
volvement in non-metastatic carcinomas. Long-term
survival rates depend on and are inversely proportional
to the number of LNs involved. Although the TNM sys-
tem is a reliable therapeutic guide, stage migration, a re-
sult of inaccurate TNM staging, has made estimation of
future survival rate inconsistent. Furthermore, stage III
colorectal cancer is subdivided into A, B, and C accord-
ing to the number of LNs involved, but this number
may vary with the total number of LNs extracted
[7,16,17].The total number of LNs retrieved may be affected by
factors such as ages, gender, body mass index, surgical
technique and the location of the tumor. Right-sided
tumors tend to yield a higher number of retrievable LNs
than left-sided tumors [18]. The NCI and RCP both rec-
ommend a minimum of 12 nodes should be retrieved
[10], but there is no general consensus on the exact
number of LNs that must be removed, and surgeons
should generally remove as many LNs as possible
[11,19]. Taking into consideration all the variables above
that could affect the total number of LNs retrieved, our
institution has maintained a high resection number over
a period of 20 years (mean 20.8, range 2–88) (Table 1).
Reviewing our data, we did not find by univariate ana-
lysis a significant correlation between the total number
of LNs resected and the survival rate of the patients
(P= 0.46). This is likely to reflect the high standards of
lymphadenectomy, with few patients in this population
being understaged. Our findings are consistent with an-
other study conducted using Surveillance, Epidemiology
Table 3 Univariate survival analysis of the patients with
stage III colorectal cancer











<50 56 95.6 ± 2.9 79.1 ± 6.7 70.3 ± 10.2
50 to 60 33 100 64.3 ± 13.2 42.9 ± 19.5
61 to 70 35 90 ± 5.5 70.1 ± 11.2 19.5 ± 16.6
> 71 39 80.5 ± 7.4 68.5 ± 10.1 68.5 ± 10.1 0.25
LNR
0 to 0.4 116 94.1 ± 2.3 77.3 ± 5.8 60.6 ± 9.9
> 0.4 41 86.2 ± 6.6 40.6 ± 13.4 0 <0.01
+LN
1 to 3 95 94.3 ± 2.5 76.3 ± 6 58.4 ± 10.5
> 4 63 89.2 ± 4.7 51.1 ± 13.1 19.2 ± 15.5 <0.05
Stage III
IIIA 13 91 ± 8.7 75.8 ± 15.6 75.8 ± 15.6
IIIB 108 94 ± 2.4 77.1 ± 5.7 56 ± 10.4
IIIC 42 84.7 ± 7.2 22 ± 17.4 0 0.01
Adjuvant
chemotherapy
No 42 78.1 ± 6.9 65.6 ± 10.4 43.5 ± 14.4
Yes 81 97.3 ± 1.9 68.2 ± 7.3 42.2 ± 18.1 0.16
Gender
Female 85 94.4 ± 2.8 66.1 ± 7.9 49.6 ± 11.7
Male 78 89.7 ± 3.7 73.3 ± 7.8 44 ± 15.2 0.10
LN resected
0 – 11 37 90.9 ± 5 59.9 ± 10.4 59.9 ± 10.4
≥ 12 123 92.1 ± 2.7 71.7 ± 6.8 40.9 ± 12.3 0.401
Grade
Well-differentiated 6 83.3 ± 15.2 41.7 ± 30.4 –––
Moderately
differentiated
92 93.6 ± 2.8 68.9 ± 7.5 51.9 ± 10.5
Poorly
differentiated
52 90.9 ± 4.4 67 ± 9.9 25.1 ± 19.6 0.61
Recurrence
No 67 83.9 ± 4.7 64.9 ± 6.9 50.5 ± 10.6
Yes 30 96.6 ± 3.4 64.4 ± 13.1 32.2 ± 17.4 0.41
Figure 2 Survival curve for node-positive patients with
colorectal cancer stratified by N stage (N1= 1 to 3 positive LNs;
N2 => 3 positive LNs).
Figure 3 Survival curve for patients with stage III colorectal
cancer, stratified as IIIA, IIIB and IIIC.
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from four different hospitals [8].
Because the total number of LNs resected was shown
to have poor prognostic value in our population, we
investigated the prognostic power of using only the num-
ber of positive LNs retrieved for prognostic estimation.
This method is currently used for prognostic estimation
in the TNM staging system, which classifies colorectal
cancer into stage III A, B, or C. According to the AJCC,
N denotes the number of positive LNs, and N1 means1–3 positive LNs collected, while N2 denotes 4 or more
positive LNs collected. With regard to this number of
positive LN method of prognostication, patients in our
population classified as N1 or N2 exhibited approxi-
mated 10-year survival rates of 58.4% and 19.2% respect-
ively (P= 0.05) (Figure 2). We divided the total number
of LNs retrieved into two groups (0–11 and ≥12 LNs
Table 4 Relationship of positive LNs (LN) removed to
total number of LN resected
Positive LNs, n Total LN removed, n (%) Total, n
0 to 11 12+
1 to 3 27 (28.4) 68 (71.6) 95 (100)_
4+ 8 (12.7 55 (87.3) 63 (100)
Total 35 123 158
LNs, lymph nodes; LNR, lymph-node ratio. P = 0.002.
Table 5 Multivariate Cox regression analysis of survival
Univariate Multivariate
Characteristics HR 95% CI P-
value
HR 95% CI P-
value
Age, years
< 50 1 0.385 to 3.051 0.879 1 0.51 to 4.68 0.44
50 – 60 1.084 0.607 to 3.872 0.366 1.54 0.46 to 4.2 0.57
60 – 70 1.533 0.938 to 6.459 0.067 1.39 0.97 to 9.12 0.06
> 70 2.462 2.98
Gender
Female 1 0.499-2.008 0.998 1 0.39 to 2.25 0.88
Male 1.001 0.93
LNR
≤ 0.4 1 1.472 to 6.234 0.003 1 1.25 to 22.12 0.02
> 0.4 3.03 5.25
Stage
IIIA 1 0.318 to 5.956 0.668 1 0.24 to 5.63 0.86
IIIB 1.377 0.836 to 17.67 0.084 1.15 0.21 to 14.64 0.60
IIIC 3.842 1.76
Positive LN
1 – 3 1 0.993 to 4.185 0.052 1 0.12 to 2.08 0.35
≥ 4 2.039 0.51
Adj chemo
No 1 0.279 to 1.235 0.16 1 0.21 to 1.27 0.15
Yes 0.586 0.52
Adj chemo, adjuvant chemotherapy; LN, lymph node; LNR, lymph-node ratio.
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egories (N1 and N2, respectively) (Table 5). Our analysis
confirmed that the number of positive LNs retrieved dir-
ectly correlated with the total number of LNs collected.
However, when we used multivariate analysis on the
number of positive LNs collected, along with pLNR,
tumor stage, and other factors such as age and gender,
the number of positive LNs was not found to be signifi-
cant (P= 0.35).
Our results are consistent with an analysis by Moug et
al. [18], who compared the number of positive LNs and
the pLNR in both univariate and multivariate analysis.
pLNR maintained its significance as a prognostic factor
in both models, whereas the number of positive LNs was
not found to be significant when computed along other
factors in the multivariate model (Tables 3, 4).
To overcome any factors that can affect the yield of LNs,
we evaluated a ratio-based classification, the positive LN
ratio (pLNR). This ratio takes into account both the total
number of LNs retrieved and the actual number of positive
LNs found. Because it does not rely on one variable, theFigure 4 The survival curve for node-positive colorectal cancer
patients stratified by lymph-node ratio.pLNR overcomes several limitations pertaining to total LN
collection, including surgical and pathological techniques,
tumor sites, and even the minimum number of LNs that
should be dissected [18]. This method has already been
used as a prognostic tool for other tumors such as gastric,
pancreatic, and breast [12-15].
Multiple cutoff points for pLNR have been have been
presented in the literature. Berger et al. used <0.05, 0.05
to 0.19, 0.2 to 0.39 and >0.4 [4]. Our pLNR stratification
using 0.4 as the cutoff point is consistent with the work
of De Ridder et al. [20], who used the same threshold.
As expected, our univariate analysis showed that patients
with stage IIIA had a better 10-years disease-free survival
rate (75.8%) than those with stage IIIB (56%) or stage
IIIC (no patients survived) (P= 0.01) (Figure 2). It also
showed that pLNR had a threshold value of 0.4, with
patients having better survival when the ratio was ≤ 0.4
(10-year survival of 60.6%, compared to 0% survival in
patients with ratio> 0.4) (P< 0.01) (Figure 4).
Using multivariate analysis, we integrated multiple fac-
tors to identify which one would be the best prognostic
determinant. We looked at age, gender, stage III (strati-
fied into A, B and C), number of positive LNs retrieved,
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found to be significant in the univariate model, lost its
power when computed alongside pLNR. Moreover,
pLNR >0.4 proved to have the most significant prognos-
tic factor (HR= 5.25, CI = 1.2 to 22.1, P< 0.05), showing
that pLNR is indeed an independent prognostic factor
for survival in patients with stage III CRC.
A limitation of our is that it was a retrospective review
and there was some loss of follow-up for a few few
patients. Nonetheless, the results confirm previous stud-
ies regarding the prognostic power of the LNR in the
colorectal disease. We have to note that our manuscript
is the first such study to be conducted in the Middle East.Conclusion
Our study confirms the prognostic value of the ratio-
based pLNR model to predic survival of patients with
stage III CRC relative to stage (AJCC), number of posi-
tive LNs, and total LNs retrieved.
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